Last reviewed · How we verify

Benzofoline (ESTRADIOL BENZOATE)

FDA-approved active Small molecule ✓ Verified May 2026 Quality 20/100

Benzofoline (generic name: ESTRADIOL BENZOATE) is a Estrogen drug. It is currently FDA-approved.

Benzofoline is a small molecule. Its modality is classified as a small molecule according to ChEMBL.

At a glance

Generic nameESTRADIOL BENZOATE
Drug classEstrogen
TargetAdenosine receptor A3, Sex hormone-binding globulin, 5-hydroxytryptamine receptor 2B
ModalitySmall molecule
Therapeutic areaNephrology
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Benzofoline

What is Benzofoline?

Benzofoline (ESTRADIOL BENZOATE) is a Estrogen drug.

What is the generic name of Benzofoline?

ESTRADIOL BENZOATE is the generic (nonproprietary) name of Benzofoline.

What drug class is Benzofoline in?

Benzofoline belongs to the Estrogen class. See all Estrogen drugs at /class/estrogen.

What development phase is Benzofoline in?

Benzofoline is FDA-approved (marketed).

What does Benzofoline target?

Benzofoline targets Adenosine receptor A3, Sex hormone-binding globulin, 5-hydroxytryptamine receptor 2B and is a Estrogen.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing